References
Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T (1998) Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in multiple sclerosis group. N Engl J Med 339(5):285–291
Vukusic S, Ionescu I, El-Etr M, Schumacher M, Baulieu EE, Cornu C et al (2004) Pregnancy in multiple sclerosis group. Brain 127(Pt 6):1353–1360
Théaudin M, Elefant E, Senat MV (2015) Natalizumab continuation during pregnancy in a patient with previous severe IRIS syndrome. J Neurol Sci 359(1–2):211–212
Friend S, Richman S, Bloomgren G, Cristiano LM, Wenten M (2016) Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurol. 16(1):150
Berger JR, Fox RJ (2016) Reassessing the risk of natalizumab-associated PML. J Neurovirol 22(4):533–535
Willis MD, Robertson NP (2016) Alemtuzumab for multiple sclerosis. Curr Neurol Neurosci Rep. 16(9):84 Review
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Frau, J., Coghe, G., Fenu, G. et al. Rescue therapy with alemtuzumab in multiple sclerosis post-natalizumab puerperium reactivation. Neurol Sci 39, 389–390 (2018). https://doi.org/10.1007/s10072-017-3135-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-017-3135-y